{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=dabrafenib&page=2", "query": { "intervention": "dabrafenib", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=dabrafenib&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-22T18:43:50.492Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01340846", "title": "A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "Warfarin", "type": "DRUG" }, { "name": "Ketoconazole", "type": "DRUG" }, { "name": "Gemfibrozil", "type": "DRUG" }, { "name": "GSK2118436 150mg", "type": "DRUG" }, { "name": "GSK2118436 75mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2012-09-03", "completion_date": "2012-11-14", "has_results": false, "last_update_posted_date": "2017-11-13", "last_synced_at": "2026-09-22T18:43:50.492Z", "location_count": 8, "location_summary": "Scottsdale, Arizona • Sarasota, Florida • Detroit, Michigan + 5 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT01340846" }, { "nct_id": "NCT02852239", "title": "Pharmacokinetics of Dabrafenib in Subjects With Renal Impairment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Impairment" ], "interventions": [ { "name": "dabrafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 22, "start_date": "2016-12-19", "completion_date": "2019-09-27", "has_results": false, "last_update_posted_date": "2020-12-09", "last_synced_at": "2026-09-22T18:43:50.492Z", "location_count": 3, "location_summary": "DeBary, Florida • Berlin, New Jersey • Raleigh, North Carolina", "locations": [ { "city": "DeBary", "state": "Florida" }, { "city": "Berlin", "state": "New Jersey" }, { "city": "Raleigh", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02852239" }, { "nct_id": "NCT03593993", "title": "A Biospecimen Collection Study in BRAF-V600E Mutated Recurrent Gliomas", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Glioma", "BRAF V600E", "Pleomorphic Xantho-Astrocytoma", "Glioblastoma" ], "interventions": [ { "name": "Surgical Cohort", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Weeks", "maximum_age": null, "sex": "ALL", "summary": "6 Weeks and older" }, "enrollment_count": 3, "start_date": "2018-05-19", "completion_date": "2023-07-07", "has_results": false, "last_update_posted_date": "2023-10-06", "last_synced_at": "2026-09-22T18:43:50.492Z", "location_count": 5, "location_summary": "Baltimore, Maryland • Boston, Massachusetts • Winston-Salem, North Carolina + 2 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Winston-Salem", "state": "North Carolina" }, { "city": "Hershey", "state": "Pennsylvania" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03593993" }, { "nct_id": "NCT02082665", "title": "Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "Rosuvastatin10 mg tablet", "type": "DRUG" }, { "name": "Midazolam 3 mg syrup", "type": "DRUG" }, { "name": "Dabrafenib 75 mg capsule", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 6, "start_date": "2015-02-19", "completion_date": "2016-08-01", "has_results": false, "last_update_posted_date": "2017-07-24", "last_synced_at": "2026-09-22T18:43:50.492Z", "location_count": 1, "location_summary": "Lebanon, New Hampshire", "locations": [ { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT02082665" }, { "nct_id": "NCT01907802", "title": "Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "BRAF Gene Mutation", "Hepatic Complication", "Renal Failure", "Solid Neoplasm" ], "interventions": [ { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacogenomic Study", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2013-08-23", "completion_date": "2015-12-16", "has_results": false, "last_update_posted_date": "2018-08-14", "last_synced_at": "2026-09-22T18:43:50.492Z", "location_count": 17, "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California + 14 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "South Pasadena", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01907802" }, { "nct_id": "NCT01940809", "title": "Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "BRAF V600E Mutation Present", "BRAF V600K Mutation Present", "Metastatic Melanoma", "Stage III Cutaneous Melanoma AJCC v7", "Stage IIIA Cutaneous Melanoma AJCC v7", "Stage IIIB Cutaneous Melanoma AJCC v7", "Stage IIIC Cutaneous Melanoma AJCC v7", "Stage IV Cutaneous Melanoma AJCC v6 and v7" ], "interventions": [ { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Trametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2013-08-28", "completion_date": "2022-03-04", "has_results": false, "last_update_posted_date": "2022-03-10", "last_synced_at": "2026-09-22T18:43:50.492Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01940809" }, { "nct_id": "NCT02915666", "title": "A Clinical Trial of Patients With Melanoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Digoxin Combination", "type": "DRUG" }, { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2016-10", "completion_date": "2017-07-17", "has_results": false, "last_update_posted_date": "2018-05-15", "last_synced_at": "2026-09-22T18:43:50.492Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02915666" }, { "nct_id": "NCT02281760", "title": "Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "BRAF V600E Mutation" ], "interventions": [ { "name": "Dabrafenib Mesylate", "type": "DRUG" }, { "name": "Trametinib Dimethyl Sulfoxide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Human Genome Research Institute (NHGRI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 9, "start_date": "2014-11-01", "completion_date": "2018-08-29", "has_results": true, "last_update_posted_date": "2021-08-31", "last_synced_at": "2026-09-22T18:43:50.492Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02281760" }, { "nct_id": "NCT04439292", "title": "Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Lymphoma", "Advanced Malignant Solid Neoplasm", "Hematopoietic and Lymphoid Cell Neoplasm", "Refractory Lymphoma", "Refractory Malignant Solid Neoplasm", "Refractory Multiple Myeloma" ], "interventions": [ { "name": "Dabrafenib Mesylate", "type": "DRUG" }, { "name": "Trametinib Dimethyl Sulfoxide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2016-01-04", "completion_date": "2026-12-31", "has_results": true, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-09-22T18:43:50.492Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04439292" }, { "nct_id": "NCT01072175", "title": "Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "GSK2118436", "type": "DRUG" }, { "name": "GSK1120212", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 430, "start_date": "2010-03-26", "completion_date": "2018-02-27", "has_results": true, "last_update_posted_date": "2019-07-05", "last_synced_at": "2026-09-22T18:43:50.492Z", "location_count": 13, "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01072175" } ] }